Kennedy Capital Management LLC lowered its position in Harpoon Therapeutics, Inc. (NASDAQ:HARP – Free Report) by 90.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,987 shares of the company’s stock after selling 476,947 shares during the quarter. Kennedy Capital Management LLC owned about 1.37% of Harpoon Therapeutics worth $214,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in the business. Delphia USA Inc. bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth $57,000. BNP Paribas Arbitrage SA increased its position in shares of Harpoon Therapeutics by 571.5% in the second quarter. BNP Paribas Arbitrage SA now owns 12,986 shares of the company’s stock worth $25,000 after acquiring an additional 11,052 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Harpoon Therapeutics during the first quarter valued at approximately $66,000. Two Sigma Investments LP lifted its position in shares of Harpoon Therapeutics by 73.6% in the 3rd quarter. Two Sigma Investments LP now owns 33,361 shares of the company’s stock valued at $32,000 after acquiring an additional 14,149 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in Harpoon Therapeutics in the 1st quarter worth approximately $32,000. Institutional investors and hedge funds own 74.01% of the company’s stock.
Harpoon Therapeutics Trading Up 0.1 %
NASDAQ:HARP opened at $23.01 on Monday. Harpoon Therapeutics, Inc. has a 1 year low of $3.11 and a 1 year high of $23.21. The firm has a 50 day moving average of $21.38 and a 200-day moving average of $12.47.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on HARP
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.
Read More
- Five stocks we like better than Harpoon Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Commvault Continues its Rally, Outpacing Tech Stocks, Midcaps
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Here’s The One Pet Stock That’s Not in the Doghouse
- 3 Warren Buffett Stocks to Buy Now
- Medtronic is a Dividend Aristocrat That Keeps Gaining
Want to see what other hedge funds are holding HARP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harpoon Therapeutics, Inc. (NASDAQ:HARP – Free Report).
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.